Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amphastar Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Amphastar Pharmaceuticals, Inc.’s stock price such as:

• Amphastar Pharmaceuticals, Inc.’s current stock price and volume
• Why Amphastar Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for AMPH from analysts
• AMPH’s stock price momentum as measured by its relative strength

About Amphastar Pharmaceuticals, Inc. (AMPH)

Before we jump into Amphastar Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Want to learn more about Amphastar Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of January 16, 2026, 12:12 PM, CST, Amphastar Pharmaceuticals, Inc.’s stock price was $26.030.

Amphastar Pharmaceuticals, Inc. is up 0.12% from its previous closing price of $26.000.

During the last market session, Amphastar Pharmaceuticals, Inc.’s stock traded between $25.420 and $26.150. Currently, there are approximately 46.47 million shares outstanding for Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 11.5, which is low compared to the Pharmaceuticals industry median of 21.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Amphastar Pharmaceuticals, Inc. Stock Price History

Amphastar Pharmaceuticals, Inc.’s (AMPH) price is currently down 2.8% so far this month.

During the month of January, Amphastar Pharmaceuticals, Inc.’s stock price has reached a high of $29.520 and a low of $25.420.

Over the last year, Amphastar Pharmaceuticals, Inc. has hit prices as high as $37.655 and as low as $20.385. Year to date, Amphastar Pharmaceuticals, Inc.’s stock is down 2.8%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amphastar Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 15, 2026, there was 1 analyst who downgraded Amphastar Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amphastar Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amphastar Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amphastar Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amphastar Pharmaceuticals, Inc. (AMPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Amphastar Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 15, 2026, Amphastar Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -6.51%, which translates to a Momentum Score of 28 and is considered to be Weak.

Want to learn more about how Amphastar Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amphastar Pharmaceuticals, Inc. Stock Price: Bottom Line

As of January 16, 2026, Amphastar Pharmaceuticals, Inc.’s stock price is $26.030, which is up 0.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amphastar Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.